F
F2G
Discovers and develops novel drugs for the treatment of life-threatening fungal diseases
At a glance
- Founded
- 1998
- Headquarters
- Manchester, United Kingdom
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning F2G.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- KNK Nominees
- MCMerifin Capital
- AVAstellas Venture
- BABankInvest
Series B and later14 investors entered at this stage
Heartcore Capital- NFNovartis Venture Fund
- ACAisling Capital
Morningside- AFAMR Action Fund
- NHNovo Holdings
- FPForbion Capital Partners
- SMSectoral Asset Management
- IGIntermediate Capital Group
- TMThe University of Manchester
Sofinnova Partners- CGCowen Group
- ASAdvent Life Sciences
- BPBrace Pharma
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
9 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about F2G on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See F2G on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.